retatrutide triple agonist glp-1 gip glucagon phase 2 obesity Retatrutide, a GIP, and receptor agonist, for people with type diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, 2 trial conducted in the USA First Retatrutide phase 3 data,
Description
I will continue to use you going forward and recommend you to others

Do not take activated charcoal within 2 hours of any medication, including your GLP-1 injection, as it can reduce medication absorption
Currently, no pure GIP agonist medications are approved for clinical use

Expected indication launch timelines for selected pipeline candidates Pharmaceutical companies are investing significantly in oral GLP-1s

doi: 10.1038/nrendo.2017.122